Calendario›REGN›REGN7508 · ROXI-APEX

REGN7508 · ROXI-APEX

REGN7508 Versus Apixaban and Enoxaparin for Thromboprophylaxis After Total Knee Arthroplasty in Adults

Ensayo de REGENERON PHARMACEUTICALS, INC. en Tromboembolismo venoso (TEV).

Fase

Fase 3

Estado

Reclutando pacientes

Participantes

2.000

previstos

Centros

47

Fin del objetivo primario

feb 2027

estimado por el promotor

Qué significa cada fase y cada estado.

Estudio de intervención, aleatorizado, doble ciego. Comenzó en jun 2025.

Qué mide

Incidencia del criterio de valoracion compuesto de tromboembolismo venoso (TEV) asintomatico o sintomatico [incluyendo muerte relacionada con TEV] (Through day 12 visit, approximately 14 days) (del registro, en inglés)

Cómo lo describe el promotor

En el documentoEn inglés, del registroThis study is researching an experimental drug called REGN7508 (called "study drug"). The study is focused on adults undergoing elective, unilateral (one side) total knee replacement surgery. The aim of the study is to see how effective the study drug is at preventing Venous Thromboembolism (VTE) and other related diseases after total knee replacement surgery. The study is looking at several other research questions, including: * What side effects may happen from taking the study drug * How much study drug is in the blood at different times * Whether the body makes antibodies against the study drug (which could make the study drug less effective or could lead to side effects)

Más ensayos de REGN

Todos los de REGN, en su ficha.

Ficha completa en ClinicalTrials.gov (NCT07015905), actualizada en sep 2026.